FORM 3

UNITED STATES SECURITIES AND EXCHANGE **COMMISSION**

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB 32	235-			
Number: 0	104			
Estimated average				
burden hours per				
response	0.5			

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)											
1. Name and Address of Reporting				quiring 3. Issuer Name and Ticker or Trading Symbol							
Person *	~	Statement (Month/Day/Year)		CymaBay Therapeutics, Inc. [CBAY]							
TRUEX PAUL F	04/01/20)								
(Last) (First) (Middle)	04/01/20	04/01/2010							5. If Amendment, Date Original		
C/O CYMABAY								Filed(Month/Day/Year)			
THERAPEUTICS, INC., 7999					(Check all applicable) _X_ Director 10% Owner Officer (give Other (specify						
GATEWAY BLVD., SUITE 130	ATEWAY BLVD., SUITE 130			Officer (g							
(Street)				title below)	title below) below)			6. Individual or Joint/Group			
NEWARK CA 04560									eck Applicable Line) iled by One Reporting Person		
NEWARK, CA 94560									led by More than One Reporting		
								Person			
(City) (State) (Zip)		Tal	ble I -	- Non-Derivat	ive	Securitie	s Ben	eficially	Owned		
1.Title of Security				nt of Securities	3.				irect Beneficial		
(Instr. 4)	(Instr. 4)			lly Owned	Ownership			Ownership			
			(Instr. 4)			rm: Direct) or	(Instr.	5)			
						direct (I)					
						nstr. 5)					
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.											
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
	Date Exercisa		1	tle and Amount o		4.	5.	onvertible	6. Nature of Indirect		
	nd Expiration I			rities Underlying		4. Conversio		nership	Beneficial Ownership		
(Month/Day/Year)		Derivative Security				or Exercis		m of	(Instr. 5)		
			(Instr	r. 4)		Price of		ivative			
D	ate Exp	iration				Derivative		urity:			
E	xercisable Date	e	Title	Amount or Num	ber	Security		ect (D) ndirect			
			Title	of Shares			(I)	nancet			
								tr. 5)			
Reporting Owners						_					

Reporting Owner Name / Address		Relationships					
		10% Owner	Officer	Other			
TRUEX PAUL F C/O CYMABAY THERAPEUTICS, INC. 7999 GATEWAY BLVD., SUITE 130 NEWARK, CA 94560	X						

Signatures

/s/ Sujal Shah, by power of attorney	04/01/2016
**Signature of Reporting Person	Date

Explanation of Responses:

No securities are beneficially owned

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of SUJAL SHAH, CHARLES MCWHERTER, MATTHEW HEMINGTON AND BRETT WHITE, signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

- (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of CymaBay Therapeutics, Inc. (the "COMPANY"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "EXCHANGE ACT") and the rules thereunder:
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact, or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by the Company or Cooley LLP, as the case may be.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 30th day of March, 2016.